Immunomodulatory effects of trans-anethole-treated Staphylococcus aureus Newman strain.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 04 2023
27 04 2023
Historique:
received:
26
11
2022
accepted:
25
04
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
27
4
2023
Statut:
epublish
Résumé
In our former studies based on a human whole-blood model infected with trans-anethole (TA)-treated Staphylococcus aureus Newman strain, we have observed that selected parameters/mechanisms of innate and acquired immune response were more enhanced in comparison to samples infected with non-treated bacteria. Due to this observation, the current study aimed to evaluate the concentration of selected proteins involved in both types of responses (IL-1α, IL-1β, IL-2, IL-6, IL-12, IL-17, TNF-α, IFN-γ, G-CSF, C5a, CCL1-CCL5, CXCL1, CXCL2, CXCL9-CXCL11, MMP-8, TLR2, and PGLYRP1) in healthy participants' plasma after blood stimulation of TA-treated S. aureus Newman strain. Determination of analyzed protein concentration was conducted using Luminex and ELISA assays. Based on the results, it has been proven that the immunomodulatory potential of TA-treated S. aureus Newman strain on increasing IL-1β, IL-6, TNF-α, IL-12, G-CSF, C5a, CCL2-CCL4, CXCL1, CXCL2, MMP-8 and PGLYRP1 levels in plasma. Moreover, it has been also demonstrated an association between TNF-α and CCL4 in a blood model infected with TA-treated cells. More research is warranted to find more underlying mechanisms involved in the effects of TA-treated S. aureus Newman in human blood, mainly whether the observed "immunity boost" can be regulated after bacteria elimination. Therefore, the potential of TA should be further explored to understand under which conditions it might help treat or prevent infections caused by S. aureus.
Identifiants
pubmed: 37106063
doi: 10.1038/s41598-023-34138-3
pii: 10.1038/s41598-023-34138-3
pmc: PMC10140024
doi:
Substances chimiques
anethole
Q3JEK5DO4K
Tumor Necrosis Factor-alpha
0
Interleukin-6
0
Matrix Metalloproteinase 8
EC 3.4.24.34
Interleukin-12
187348-17-0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6881Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2021 May 27;16(5):e0252046
pubmed: 34043679
Chem Immunol Allergy. 2003;83:95-114
pubmed: 12947981
Blood. 2011 Jul 7;118(1):9-18
pubmed: 21562044
Front Cell Infect Microbiol. 2020 Dec 23;10:582803
pubmed: 33425777
Cell Physiol Biochem. 2019;52(4):908-921
pubmed: 30964608
J Immunol. 2015 Feb 15;194(4):1417-21
pubmed: 25595774
J Immunol. 2000 Oct 15;165(8):4515-21
pubmed: 11035091
Am J Pathol. 2008 Jul;173(1):144-53
pubmed: 18556780
Trends Immunol. 2019 Jul;40(7):648-664
pubmed: 31155315
Evid Based Complement Alternat Med. 2017;2017:2505610
pubmed: 28316634
Poult Sci. 2021 Dec;100(12):101489
pubmed: 34695630
Nature. 2007 Oct 18;449(7164):819-26
pubmed: 17943118
J Innate Immun. 2018;10(5-6):432-441
pubmed: 29642066
Pharmaceuticals (Basel). 2013 Nov 25;6(12):1451-74
pubmed: 24287491
Front Immunol. 2012 Dec 10;3:368
pubmed: 23233853
Thromb Haemost. 2013 Oct;110(4):807-25
pubmed: 23925450
Acta Derm Venereol. 2020 Aug 17;100(15):adv00232
pubmed: 32618347
Biomolecules. 2020 Aug 03;10(8):
pubmed: 32756359
Front Microbiol. 2014 Nov 26;5:627
pubmed: 25505454
Biochem Biophys Res Commun. 2011 Mar 18;406(3):449-53
pubmed: 21333631
Genes Immun. 2003 Mar;4(2):87-94
pubmed: 12618855
Curr Opin Immunol. 2003 Aug;15(4):408-15
pubmed: 12900272
Nat Rev Immunol. 2016 May 27;16(6):378-91
pubmed: 27231052
Int Immunol. 2010 Oct;22(10):827-38
pubmed: 20739460
Trends Immunol. 2013 Jul;34(7):317-28
pubmed: 23540649
Clin Exp Immunol. 1999 Jan;115(1):189-95
pubmed: 9933441
Molecules. 2021 Apr 23;26(9):
pubmed: 33922508
J Pharm Pharmacol. 2012 Apr;64(4):610-6
pubmed: 22420667
PLoS Pathog. 2022 Apr 21;18(4):e1010430
pubmed: 35446923
Int J Mol Sci. 2022 May 20;23(10):
pubmed: 35628562
J Leukoc Biol. 2001 Sep;70(3):439-46
pubmed: 11527994
FASEB J. 2007 Aug;21(10):2580-91
pubmed: 17392479
J Anim Sci. 2012 Aug;90(8):2774-83
pubmed: 22328722
Immunology. 2015 Jul;145(3):429-42
pubmed: 25752767
Eur J Immunol. 1996 Mar;26(3):659-68
pubmed: 8605935
J Ethnopharmacol. 2011 Sep 1;137(1):909-13
pubmed: 21782918
Lett Appl Microbiol. 2022 Apr;74(4):513-518
pubmed: 34904269
Circulation. 2001 Oct 16;104(16):1899-904
pubmed: 11602491
J Biol Chem. 2013 Jun 7;288(23):16282-16294
pubmed: 23632023
Int J Antimicrob Agents. 1996 May;7(1):33-40
pubmed: 18611733
Virol J. 2017 Dec 4;14(1):234
pubmed: 29202792
Inflamm Regen. 2019 Jun 6;39:12
pubmed: 31182982
Am J Pathol. 2016 Sep;186(9):2337-52
pubmed: 27470712
Pathogens. 2016 Mar 17;5(1):
pubmed: 26999219
BMC Immunol. 2012 Jul 09;13:38
pubmed: 22776294
Biomed Pharmacother. 2002 May;56(3):159-62
pubmed: 12046688
Int J Mol Sci. 2020 Jun 11;21(11):
pubmed: 32545315
Front Cell Infect Microbiol. 2017 Jun 30;7:286
pubmed: 28713774
Int J Mol Sci. 2022 May 03;23(9):
pubmed: 35563475
J Infect Dis. 1991 Mar;163(3):579-83
pubmed: 1704903
Molecules. 2022 May 28;27(11):
pubmed: 35684426
J Biol Chem. 2000 Aug 11;275(32):24490-9
pubmed: 10827080